India · Delayed Price · Currency is INR Alembic Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY26 revenue rose 11% year-over-year, with strong growth in ROW and steady U.S. expansion despite pricing pressure. India branded business grew 6%, and the company is on track to launch its first U.S. branded product, though initial margin drag is expected.
-
Q2 revenue grew 16% year-on-year with strong international and ROW market performance, while gross margin remained stable and EBITDA margin improved. Acquisition of UTILITY Therapeutics marks entry into U.S. branded drugs, with near-term profitability impacted by launch investments.
-
Q1 FY26 saw 10% revenue growth, margin expansion, and strong international performance, while India growth lagged due to execution challenges. U.S. and ROW businesses are expected to grow 10-15% for the year, with API segment facing near-term pricing pressure.
Fiscal Year 2025
-
Q4 FY25 saw 17% revenue growth and 9% EBITDA growth, with strong U.S. and ROW generics performance and robust animal health gains. FY26 guidance targets double-digit growth across key segments, increased R&D for complex products, and improved margins as new facilities scale.
-
Q2 FY25 saw 3% revenue growth and 12% net profit rise, with strong specialty and animal health performance offsetting API decline. H2 is expected to be stronger, driven by new launches in the U.S. and ROW, while gross margin remains robust at 74%.
-
Revenue grew 5% year-over-year to INR 1,562 crores, with EBITDA up 14% and net profit up 12%. US generics rose 18%, while API declined 15% due to customer and pricing issues. Margins remain stable, and supply constraints in ROW are expected to ease in coming quarters.